The therapeutic potential of targeting these pathways, such as through the use of fibroblast growth factor 21 (FGF21), has been explored by Weng et al. [231], where the authors reported a reduction in inflammation and oxidative stress in salt-sensitive, hypertension-induced nephropathy. Here, FGF21 is linked to kidney disorder.